4TEEN4 Pharmaceuticals is pleased to announce the successful final closing of its Series C financing round. With the last closing completed in February, the round has now reached a total volume of more than €64 million.
The strong support from both existing and new investors reflects continued confidence in 4TEEN4’s scientific approach and the development of invobenitug (procizumab), the company’s lead therapeutic candidate targeting circulating DPP3 in cardiogenic shock.
The proceeds from the Series C financing will support the ongoing clinical program, as well as the continued advancement of the company’s biomarker and diagnostic activities.
This milestone represents an important step in accelerating 4TEEN4’s mission to develop innovative therapies for critically ill patients.
